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An immunoperoxidase method, using a monoclonal anti-
body which recognizes 4-aminobiphenyl (4-ABP)-DNA
adducts, was developed for the detection and quantitation
of DNA damage in bladder tissue and applied to stored
paraffin blocks of transurethral resection specimens of 46
patients with Tl bladder cancer. Mean relative staining
intensity for 4-ABP-DNA adducts was significantly higher
in current smokers (275 ± 81, n = 1A) compared to
nonsmokers (113 ± 71, n = 22) (P < 0.0001). There was
a linear relationship between mean levels of relative staining
and number of cigarettes smoked with lower levels in the
1-19 cigiday group (205 ± 30, n = 5), compared to the
20-40 (289 ± 40, n = 7) and the >40 cigiday group (351
± 57, n = 3)(P < 0.001). Nuclear overexpression of p53,
analyzed by immunoperoxidase staining, was observed in
27 (59%) of the 45 stage Tl tumors analyzed. There was
a significant correlation between p53 overexpression and
recurrence of disease (odds ratio = 123, P < 0.01). Nuclear
staining of p53 was also correlated with smoking status,
cigVday and 4-ABP-DNA adducts. This work demonstrates
that the immunohistochemical method has sufficient sensit-
ivity for detection of 4-ABP-DNA adducts in human bladder
samples. The method has several advantages including
small sample size, the possibility of retrospective analysis
of stored paraffin blocks, the ability to analyze binding in
specific cell types, and a relatively low cost
Introduction
Bladder cancer is strongly linked to occupational and environ-
mental exposures to chemical carcinogens with tobacco smok-
ing considered an important cause (1). In western countries
-50% of male and 25% of female cases may be attributable to
smoking (2). Carcinogens in cigarette smoke include polycyclic
aromatic hydrocarbons, nitrosamines, benzene and aromatic
amines (3). In contrast to cancer of the upper respiratory tract,
•Abbreviations: 4-ABP, 4-ammobiphenyl; GC/MS, gas chromatography/mass
spectroscopy, 1HC, immunohistochemical; TUR, transurethral resection; OR,
odds ratio; CI, 95% confidence interval.
for which tobacco specific A/-nitrosamines and polycyclic
aromatic hydrocarbons have been implicated as causative
agents, bladder cancer is more likely caused by aromatic
amines (4).
4-Aminobiphenyl (4-ABP*), a known bladder carcinogen
in both humans and experimental animals, is metabolically
activated to several electrophilic intermediates which cova-
lently bind to DNA (4). The predominant adduct is N-(2'-
deoxyguanosin-8-yl)-ABP, which accounts for ~70% of the
adducts formed (5). The covalent modification of DNA by
carcinogens such as 4-ABP appears to be a critical event in
chemical carcinogenesis. As a result, the analysis of carcino-
gen-DNA adducts is considered a useful means of assessing
exposure to chemical carcinogens. Evidence for human expo-
sure to 4-ABP and its metabolic activation to a reactive
intermediate was initially obtained from the detection of 4-
ABP-hemoglobin adducts, with higher levels being observed
in cigarette smokers versus nonsmokers (6-7). More recently,
a number of methods have been developed for quantitation of
DNA damage resulting from environmental or occupational
exposure to 4-ABP including immunoassays, 32P-postlabeling-
HPLC and gas chromatography-mass spectroscopy (GC-MS)
(8). These methods require the isolation of bulk DNA from
tissues and thus do not allow the detection of adducts in
specific cell types. In addition, some methods require relatively
large amounts of DNA for analysis, limiting their application.
We previously developed a monoclonal antibody, 3C8,
recognizing 4-ABP-DNA adducts (9). The antibody is highly
specific for 4-ABP-DNA and, at the highest concentrations
tested, did not recognize the DNA adducts of several other
aromatic amines including 1-aminopyrene, 8-nitro-l-aminopyr-
ene and 6-nitro-l -aminopyrene. A quantitative immunofluo-
rescence method for detecting adducts was developed and
tested in 4-ABP-treated mice. There was a dose-related increase
in specific nuclear staining in liver and bladder. DNAs extracted
from liver tissues were also analyzed for 4-ABP adducts after
alkaline hydrolysis by GC-MS. A good correlation (r =
0.98, P < 0.0001) was found between DNA damage levels
determined by the two methods.
p53 is a common target for carcinogenic agents and fre-
quently mutated in bladder cancers. The product of the gene
is a nuclear phosphoprotein involved in cell cycle regulation.
Levels of p53 increase in response to DNA damage, arresting
the cell cycle in Gl phase and allowing time for DNA repair
(10). Compared with the wild-type protein, most mutant p53
products have a prolonged half-life and can be detected
using immunohistochemical (IHC) assays. For patients with
superficial bladder cancer, a correlation between staining for
p53 and invasive behaviour of the tumor with a poor clinical
outcome has been proposed (11-13). p53 overexpression is
also associated with cigarette smoking (14—16).
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In this study, we report on the development of an immunop-
eroxidase method for direct quantitation of 4-ABP-DNA
adducts in paraffin embedded bladder samples of patients with
Tl bladder cancer. We assessed the relationship between the
levels of 4-ABP-DNA adducts and cigarette smoking status.
We also investigated the relationship between p53 overexpres-
sion and cigarette smoking or 4-ABP-DNA adduct levels. One
additional aim of the study was to confirm the usefulness of
IHC staining of p53 overexpression as a prognostic marker in
superficial bladder cancer.
Materials and methods -
The medical charts of consecutive patients with bladder cancer, seen at the
Department of Urology of the Catholic University in Rome from May 1985
to May 1989, were reviewed. We studied those patients with transurethral
resection (TUR) specimens diagnosed as transitional cell carcinoma at the TI
stage according to the TNM system, with no previous adjuvant therapy or
history of bladder cancer. We obtained a total of 46 consecutive cases (37
males and 9 females). All tumors were pathologically graded as grade 1 (n =
11), 2 (n = 23) and 3 (n = 12). The median age of the patients was 64 years
(range 47 to 74 years) median follow-up after TUR was 92.5 months (range
72 to 118 months). Of the 46 patients, 24 (52%) developed a recurrence and
6 (13%) of these progressed to a more advanced stage and higher pathological
grade. Patients developing muscle-invasive tumors underwent a radical cystec-
tomy. Information on ever/never smoking was abstracted from the medical
charts for all 46 patients. Patients were classified as smokers if they smoked
for a defined period during their lifetime and were currently smokjng at the
time of diagnosis (n = 24). Patients smoking <200 cigarettes during their
lifetime and who never used any other tobacco-related products were classified
as nonsmokers (n = 19). Patients who stopped smoking at least two years
before cancer diagnosis were classified as exsmokers (n = 3). Information
about the type of tobacco (black air cured or blond flue cured) was not
avalaible. Information on number of cigarettes per day (cig7day) was avalaible
for only 15 patients. In this group, smoking exposure was classified into three
categories: 1-19 ( n= 5), 20-40 (/i = 7) and >40 (n = 3) cigJday.
Immunoperoxidase detection of 4-ABP-DNA adducts
Five micrometer sections of archival formalin-fixed, paraffin-embedded blad-
der tissue were placed on slides coated with poly-L-Lysine (Sigma, Chemical
Co., St Louis Md). 4-ABP-DNA adducts were analyzed essentially as described
previously (9). After deparaffinization, slides were washed with PBS, treated
with RNase (100 mg/ml Sigma) at 37°C for 1 h and washed with PBS. They
were treated with proteinase K (10 mg/ml, Sigma) at room temperature for
10 min to remove histone and non-histone proteins from DNA and increase
antibody accessibility. To denature DNA, slides, after washing in PBS, were
incubated with 4N HCI for 10 min and then with 50mM Tris Base for 5 min,
both at room temperature. After washing with PBS, slides were incubated
with 0.3% H J O J in methyl alcohol at room temperature for 30 min to quench
endogenous peroxidase activity. Nonspecific binding was blocked with 1.5%
normal horse serum and slides incubated with the anti-4-ABP-DNA mono-
clonal antibody 3C8 (9) (1:5 dilution in 1.5% horse serum) overnight at 4°C.
Tissues were then incubated with a biotinylated horse anti-mouse secondary
antiserum (Vector Laboratories, Burlingame, CA), and reactivity was visualized
with ABC and diaminobenzidine (DAB) kits (Vector) used as directed by the
manufacturer. Slides were dehydrated and cleaned in serial ethyl alcohol and
xylene and mounted with Permount (Fisher Scientific, Pittsburgh, PA). Liver
tissue from a Balb/c femal mouse treated with 80 mg/kg 4-ABP and sacrificed
24 h later was used as a positive control. Normal bladder from a TUR
specimen of a nonsmoking patient was used as a negative control. To
demonstrate staining specificity, a subset of slides from smokers and non-
smokers were pretreated with DNase (100 mg/ml for 1 h at 37°C) before
staining, stained with a nonspecific antiserum (8G1; 1:10 dilution of hybridoma
supernatant) recognizing DNA damage produced by the photoactivated drug
8-methoxypsoralen (17) or with antiserum preabsorbed with 4-ABP-DNA
(1 u.g/nl for 20 min at room temperature) before use. Because of the limited
number of slides from each individual these controls could not be run for all
samples. A Cell Analysis System 200 microscope (Becton Dickinson, San
Jose, CA) was used to measure the relative intensity of nuclear staining in
100 randomly selected cells of bladder epithelium using the Cell Measurement
Program software package. Data presented are the object average optical
density multiplied by 1000.
Immunoperoxidase detection ofp53 overexpression
Immunohistochemical staining for p53 was performed essentially as for 4-
ABP except thai pretreatment with RNase, proteinase K and HCI was omitted.
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4-ABP-DNA relative staining intensity
Fig. 1. Distribution of relative intensity of peroxidase staining for 4-ABP-
DNA adducts in human urinary bladder cancer mucosa of smokers and
nonsmokers.
Tissue sections were incubated overnight at 4°C with the mouse monoclonal
antibodies PAb 1801 (Ab2 Oncogene Science Inc. Cambridge MA) at 1:100
dilution and DO-7 (gift of Dr D.P.Lane, Dept. of Biochemistry, University of
Dundee, Scotland, UK) at 1:1400 dilution. A counterstain of 1% modified
Harris hematoxilin was used. A colon carcinoma with known p53 mutation
and documented accumulation of p53 protein by immunohistochemical analysis
was used as a positive control. Normal urothelium, used as a negative control,
demonstrated no immunoreactivity.
Three investigators, without prior knowledge of tumor stage or clinical
follow-up, separately reviewed the slides to determine p53 staining. Depending
on the percentage of nuclei exhibiting positive staining, tumors were categor-
ized as follows: no nuclear reactivity, patchy (1-24% positive nuclei),
heterogeneous nuclear reactivity (25-49% of positive nuclei) and intense
homogeneous nuclear reactivity (50-100% of nuclei).
Data analysis
Differences between two means was determined by (-test and one-way analysis
of variance was used to compare the distribution of 4-ABP relative staining
intensity between different categories. Data were analyzed both as a continous
variable and dicotomized into high and low relative staining intensity. As the
distribution of 4-ABP relative staining was clearly bimodal (Figure 1), we
arbitrarily chose a relative staining intensity of 179 as the cut-off point
between low and high staining. Odds ratios for p53 overexpression and
recurrence and for p53 and smoking status and 4-ABP staining intensity were
estimated and tested by x2 test with or without Yates' correction for continuity
depending on the number in each entry of 2X2 tables. All statistics were
carried out by SAS and EGRET software packages.
Results
Immunoperoxidase quantitation of 4-ABP-DNA adducts
Higher levels of specific nuclear staining were observed in
bladder tissue of smokers compared to nonsmokers. Represent-
ative staining of a smoker and a nonsmoker are illustrated in
Figure 2A and B, respectively. Staining was quantitated in
100 randomly selected cells in the bladder epithelium. To
demonstrate the staining specificity, several samples were
stained under various control conditions. Because limited slides
were available for each individual, these controls were run on
different subjects. Preabsorption of primary antibody with 4-
ABP-DNA before use decreased relative staining intensity in
a smoker from 271 ± 30 to 52 ± 15 (Figure 2C) and in a
nonsmoker from 132 ± 13 to 33 ± 2 (data not shown).
Staining with a nonspecific antibody recognizing DNA damage
produced by 8-methoxypsoralen decreased staining from 326
± 37 to 44 ± 4 in a smoker (Figure 2D) and from 79 ± 5 to
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Fig. 2. Immunoperoxidase staining for 4-ABP-DNA of tumor bladder tissue from a smoker (A) (mean relative staining intensity= 133 ± 35) and a nonsmoker
(B) (mean = 86 ± 8). As controls, tumor mucosa from two different smokers were stained with antibody 3C8 preabsorbed with 4-ABP-DNA before use (C)
(mean = 52 ± 15) and with a nonspecific antibody recognizing 8-methoxypsoralen-DNA (D) (mean = 48 ± 6) (X 400).
48 ± 6 in a nonsmoker (data not shown). Pretreatment of
slides with DNase also decreased mean relative staining from
300 ± 33 to 33 ± 4 in a smoker and from 56 ± 3 to 34 ± 3
in a nonsmoker as did omission of primary antibody, performed
only in a smoker (from 179 ± 15 to 44 ± 4) (data not shown).
There was an ~3-fold range in relative staining in both smokers
(179 ± 15 to 427 ± 98) and the combined non and exsmokers
(56 ± 3 to 170 ± 40). Because levels of 4-ABP-DNA adducts
in urothelial DNA of exsmokers (123 ± 26, n = 3) were not
significantly different from those of nonsmokers (111 ± 76,
n = 19), they were combined for further analysis. Mean
relative staining in current smokers (275 ± 81, n = 24) was
significantly (P < 0.0001) elevated compared to nonsmokers
(113 ± 71, n = 22) (Table I, Figure 3A), mean level of
relative staining increased with dose with lower levels in the
1-19 cigVday group (205 ± 30, n = 5), compared to the 20-
40 (289 ± 40, n = 7) and the >40 cig./day (351 ± 57, n =
3) {P < 0.001) (Figure 3B).
4-ABP-DNA adducts were not associated with age (P =
0.559) or sex (P = 0.961). A grading-related increase in mean
relative staining was observed, with lower levels of 4-ABP-
DNA adducts in the Gl (159 ± 102) compared to the G2
(206 ± 103) or G3 grade (217 ± 134) (Table I). This
relationship was not statistically significant (P = 0.559).
Immunoperoxidase quantitation of p53 overexpression
Nuclear overexpression of p53 was observed in 27 (58.6%) of
the 45 stage Tl tumors analyzed. Typical staining was localized
Table I. Immunohistochemical staining for 4-ABP-DNA adducts in bladder
tumor tissue and clinico-pathological variables, smoking status and p53
nuclear overexpression
Variables
Sex
Age
Grading
Recurrence
Smoking
p53 staining
Group
male
female
<65
*65
Gl
G2
G3
No
Yes
nonsmoker"
smoker
Negative
Positive
No.
37
9
23
23
11
23
12
22
24
22
24
18
27
Mean relative staining intensity
(± SD)
197 (114)
199 (104)
217 (125)
186(100)
159(102)
206(103)
217 (134)
194(122)
201 (102)
113(71)
275 (81)b
160(91)
227 (116)c
"Includes three exsmokers.
br-test with P < 0.0001 compared to smokers.
cMest with P < 0.05 compared to p53 negative tumors.
in the nuclei with variable but not appreciable cytoplasmic
staining (data not shown). Identical results were obtained with
both antisera. Depending on the percentage of positively
stained cells, three groups of tumors were identified. In 5 of
46 tumors (10%), <25% of cells exhibited a positive staining
reaction for p53. In 12 samples (26%), the number of cells
913
 at European Institute of O
ncology on M
ay 12, 2016
http://carcin.oxfordjournals.org/
D
ow
nloaded from
 
Non-smokers Smokers 1-19 20-40 >40 Cig./day
Fig. 3. Comparison of relative intensity of staining for 4-ABP-DNA damage of tumor bladder mucosa of smokers and nonsmokers (A) and comparison of
relative intensity in relation to cigiday (B). Median values are shown by the line within the points.
stained positively was >25% and <50%. In the third group
of 10 tumors (21%), nuclear reactivity was present in >50%
of cells. With a median follow-up of 92.5 months, 24 (52%)
of 46 patients presented a recurrence and 6 (13%) of these
progressed to a more advanced stage. Twenty (83%) of the 24
patients with recurrences were positive for p53 staining. A
strong correlation was found between p53 nuclear overexpres-
sion and recurrence of disease (OR=12.3, P < 0.01). p53
was not associated with other clinico-pathological variables
analyzed (age, sex, and grade). Nuclear staining of p53 protein
was observed in 17 of 24 (66%) current smokers and in 10 of
21 (45%) nonsmokers. There was a nonsignificant association
between p53 overexpression and smoking status with an OR
of 2.7 (CI 0.7-13.7, P = 0.099). We found a dose-response
relationship between cigarettes smoked per day and p53
overexpression; corrected odds ratios were 3.0 (P > 0.1) and
19.0 (P < 0.05) for 1-19 cig./day and 3=20 cig./day, respect-
ively, compared with nonsmokers. A relationship was also
found by univariate (P < 0.05) and stratified (OR=2.9, P =
0.099) analysis between 4-ABP relative staining intensity
and p53.
Discussion
Previously, we used an indirect immunofluorescence method
to detect 4-ABP-DNA adducts in liver and bladder of treated
mice. A good correlation between relative fluorescence intens-
ity and DNA adduct levels in liver tissue determined by GC/
MS was observed (9). Here, a quantitative immunoperoxidase
method for direct monitoring of smoking related 4-ABP-DNA
adducts in paraffin embedded specimens of human tumor
bladder tissue was developed. This method is an improvement
over the previous immunofluorescence method since it allows
direct quantitation of staining on the slides. As for the
immunofluorescence method, we obtained a dose-response
relationship between immunoperoxidase relative staining
intensity of frozen and paraffin sections of liver tissue and
adduct levels measured by GC/MS (not shown).
Our results indicated that the prevalence of 4-ABP-DNA
adducts in human bladder is significantly associated with
smoking status (Figure 3A). A linear dose-response relation-
ship was observed between levels of staining for 4-ABP-DNA
and number of cigarettes smoked per day (Figure 3B). Quitting
914
smoking is associated with a dramatic drop in the levels of 4-
ABP-DNA adducts. The exsmokers who had quit a minimum
of two years prior to diagnosis had mean relative staining
levels similar to those of nonsmokers. The weak staining
observed in nonsmokers may be due to passive smoking
exposure. Low levels of 4-ABP-hemoglobin adducts have been
observed in nonsmokers (6-8) and suggested to be due to
exposure to environmental tobacco smoke (8,18). 4-Nitrobi-
phenyl in diesel exhaust has also been suggested as a source
of 4-ABP adducts (19). However, low levels of nonspecific
binding of primary or secondary antisera may also be respons-
ible for the weak staining in nonsmokers. We previously
demonstrated no cross-reactivity of 3C8 with several other
aromatic amine-DNA adducts but there may still be recognition
of other untested adducts (9). The controls run here also
confirmed the specificity of the method on human samples.
It is difficult to convert relative staining intensity of human
bladder tissue to absolute adduct levels. However, the standard
curve of immunoperoxidase staining of paraffin liver tissue of
4-ABP-treated-mice versus absolute adduct levels determined
by GC/MS could be used to obtain an estimate. These data
suggest that the human samples contain ~l-7 adducts/106
nucleotides. The limitations of this estimate are the species
and tissues extrapolations and the possibility of multiple
exposures in humans compared to the single 4-ABP exposure
of mice. It would be necessary to derive a standard curve of
human bladder tissues to overcome these limitations. Lower
levels of adducts have been reported using other methods of
analysis. An immunoassay using a polyclonal antiserum to the
4-ABG-guanosine monoadduct of DNA isolated from normal
urinary bladder found levels of adduct up to 5/107 (20)
while a GC/MS method found levels up to 4/108 (21). [32P]
Postlabeling with the butanol extraction procedure of bladder
biopsy samples indicated a mean level of A'-(2'-deoxyguanosin-
yl)-ABP of 1.5/108 in smokers (5). Adduct levels have also
been monitored in exfoliated bladder cells by postlabeling.
Using an excess ATP method, levels in exfoliated cells of
black and blond tobacco smokers were 8.8 and 7.7/109,
respectively (22).
The grading-related increase in mean relative staining shows
that 4-ABP-DNA adducts are related to histologic changes in
the epithelium of urinary bladder. A previous report (18)
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showed that smoking habit is associated with an increase of
cell rows and number of cells with atypical nuclei. In our
study, poorly differentiated Tl bladder cancer had higher mean
staining than moderately or well differentiated tumors.
There was an ~3-fold range in relative staining in both
smokers and nonsmokers, suggesting the importance of interin-
dividual differences in metabolism of 4-ABP and/or repair of
DNA damage. Furthermore, the total distribution of 4-ABP-
DNA adduct mean staining intensity in current smokers and
nonsmokers was clearly bimodal, with two convex curves
(Figure 1). Liver N-acetyltransferase (NAT2) and bladder
NAT1, because of their major role in the biotransformation of
aromatic amines and their polymorphisms affecting metabol-
ism, would be expected to modulate the levels of 4-ABP-DNA
adducts in the target organ (19).
Tl bladder cancer is an interesting model to study the
impact of the p53 gene product on the development and
progression of cancer. First, the high incidence permits a
thorough investigaton of this tumor. Furthermore, in contrast
to other tumors, all stages of the disease from precursor lesions
and Tis (in situ) to metastatic disease can be examined,
allowing the analysis of molecular alterations in the course of
malignant disease. The present study confirms earlier reports
(11-13) which demonstrated that p53 nuclear overexpression
occurs with high frequency in Tl bladder tumors. The multivar-
iate analysis demonstrated p53 to be an important and independ-
ent prognostic factor for disease recurrence and progression.
Thus, loss of p53 function is an important step in the develop-
ment of bladder cancer.
Increased prevalence of p53 nuclear staining was found in
smokers compared to nonsmokers. Spruck et al. (14) first
reported a relationship between smoking status and p53 geno-
type abnormalities, consistent with other successive findings
(15—16). Our results also showed an association between p53
overexpression and smoking status or cigarettes per day. In
addition, we explored the possible dose-response relationship
between 4-ABP-DNA adduct staining and p53. The association
by stratified analysis was significant, supporting the hypothesis
that 4-ABP derived from cigarette smoking may induce p53
mutations as a result of direct interaction with DNA.
We and others have used IHC to analyze DNA damage in
humans resulting from exposure to several chemical carcino-
gens. Aflatoxin Bl-DNA adducts have been detected by
immunofluorescence staining in liver tissue obtained at the
time of surgery (20) as well as in biopsies obtained for
diagnosis of liver cancer (21). Polycyclic aromatic hydrocarbon
adducts in oral mucosa cells of smokers (22), lymphocytes of
coke oven workers and controls (23) and lung, cervix and
placental tissues (24) have been monitored by immunofluores-
cence or immunoperoxidase techniques. C^-ethyl guanine has
also been monitored in lymphocytes of patients treated with
alkylating chemotherapeutic agents (25).
The immunoperoxidase method for 4-ABP-DNA developed
here will be useful to further investigate interindividual differ-
ences in damage and, potentially, the risk for cancer develop-
ment. This method provides both good selectivity and
sensitivity which are required for the detection and quantifica-
tion of 4-ABP-DNA adducts at the levels found in human
samples and can be applied to stored paraffin samples (our
specimens were 6-10 years old). Immunohistochemical detec-
tion of 4-ABP-DNA adducts as a potential marker of exposure
in case-series studies has several advantages: retrospective
analysis on paraffin embedded specimens, requirement for
small numbers of cells, making the method applicable to
biopsy samples and exfoliated cells, possibility to easily collect
many samples, high cell-specificity in the detection of the
adducts and relatively low cost of the methodology. The results
of this pilot study indicate that this analysis is a promising
addition to biomonitoring studies.
Acknowledgements
This work was supported by NIH grant ES05116, the Lucille P. Markey
Charitable Trust and the Toniolo Institute Award for biomedical research.
References
1. International Agency for Research on Cancer. (1986) Monographs on the
evaluation of the carcinogenic risk of chemicals to humans. IARC, vol.
38, Tobacco Smoking. Lyon, France.
2. Parkin.D.M., Leara,E. and Muir.C.S. (1988) Estimates of the worldwide
frequency of sixteen major cancer in 1980. Int. J. Cancer, 41, 184-197.
3. Patnakanos.C and Hoffmann.D (1979) Chemical studies on tobacco
smoke. J. Anal. Toxicoi, 3, 150-154.
4. Miller,E.C. (1978) Some current perspectives on chemical carcinogenesis
in humans and experimental animals. Cancer Res., 38, 1479-14%.
5.Talaska,G., Al-Jubun,A.Z. and Kadlubar,F. (1991) Smoking related
carcinogen-DNA adducts in biopsy samples of human urinary bladder
identification of A'-(deoxyguanosine-8-yl)-4-aminobiphenyl as a major
adduct. Proc. Natl Acad. Set. USA, 88, 5350-5354.
6.Bryant,N.S., Skipper,P.L., Tannenbaum.S. and Maclurejvl. (1987)
Hemoglobin adducts of 4-aminobiphenyl in smokers and non smokers.
Cancer Res., 47, 602-608.
7,Bryant,N.S., Vineis.P., Skipper.P.L. and Tannenbaum.S.R. (1988)
Hemoglobin adducts of aromatic amines: association with smoking status
and type of tobacco. Proc. Natl Acad. Sci.USA, 85, 9788-9791.
8.Skipper,P. and Tannenbaum.S. (1994) Molecular dosimetry of aromatic
amines in human populations. Environ. Health Perspect., 102, 17—21.
9.AI-AtrashJ., Zhang.YJ., Lin,D., Kadlubar.F. and Santella.R.M. (1995)
Quantitative immunohistochemical analysis of 4-aminobiphenyl-DNA in
cultured cells and mice: comparison to gas chromatography/mass
spectroscopy analysis. Chem. Res. Toxtcol., 8, 747-752.
10.Levine.AJ., MomandJ. and Finlay.C.A. (1991) The p53 tumor suppressor
gene. Nature, 351, 453-455
1 l.SarkisA, Dalbagni.C, Cordon-Cardo,C, Zhang,Z.F., SheinfeldJ., Fair,W.,
Herr.H. and Reuter,V. (1993) Nuclear overexpression of p53 protein in
transitional cell carcinoma of the bladder. J. Natl Cancer Inst., 85, 53-58.
12.Gardiner,R., Walsh.M., Allen.V, Rahmen,S., Saramatunga,M., Seymur.G.
and Lavin.M. (1995) Immunohistological expression of p53 in primary
Tl transitional cell bladder cancer in relation to tumour progression. Br.
J. Urol., 3, 526-532.
13.SerthJ., Kuczyc.M., Bokemeier.C, Hervatin.C, Mafe,R., Tan,H. and
Jonas,U. (1995) p53 immunohistochemistry as an independent prognostic
factor for superficial transitional cell of the bladder. Br. J. Cancer, 71,
201-205.
14.Spruck,C. Ill, Rideout,W. Ill, 01umni,A. et al. (1993) Distinct pattern of
p53 mutations in bladder cancer relationship to tobacco usage. Cancer
Res., 53, 1162-1166.
15.Habuchi,T, Takchashi.R., Yamada,H. et al. (1993) Influence of cigarette
smoking and Schistosomiasis on p53 gene mutation in urothelial cancer.
Cancer Res., 53, 3795-3798
16.Zhang,Z., Sarkis,A., Cordon-Cardo.C. et al. (1994) Tobacco smoking,
occupation and p53 nuclear overexpression in early stage bladder cancer.
Cancer Epidemiol. Biomarkers Prev., 3, 19-24.
17.Zhang,Y, Li.Y., De Leo.V. and Santella,R.M. (1990) Detection of DNA
adducts in skin biopsies of coal tar-treated psoriasis patients:
immunofluorescence and 32P-postlabeling. Skin Pharmacol., 8, 171-179.
18. Hammond.S.K., CoghlinJ., Gann,P.H., Paul.M., Taghizadeh,K., Skiper.P.L.
and Tannenbaum.S.R. (1993) Relationship between environmental tobacco
smoke exposure and carcinogen-hemoglobin aduct levels in nonsmokers.
J. Natl Cancer Inst., 85, 474477.
19.Tompkins,B.A., Brazell.R.S., Roth.M.E. and Ostrum.V.H. (1984) Isolation
of mononitrated polycyclic aromatic hydrocarbons in paniculate matter
by liquid chromatography and determination by gas chromatography with
the thermal energy analyzer. Anal. Chem,, 56,781-786.
20. Kadlubar,F.F., Talaska,G., Lang.N.P, Benson.R.W. and Roberts.D.W.
(1988) Assessment of exposure and susceptibility to aromatic amine
carcinogens. In Bartsch.H., Hemminki,K. and O'Neill.I.K. (eds), Methods
915
 at European Institute of O
ncology on M
ay 12, 2016
http://carcin.oxfordjournals.org/
D
ow
nloaded from
 
G.Curigllano et at.
for detecting DNA damaging agents in humans: applictions in cancer
epidemiology and prevention. IARC No. 89, Lyon, France, pp. 166-174.
21.Lin,D. LayJ.O., BryanuM.S., Malaveille.C, Friesen.M., Bartsch.H.,
Lang,N.P. and Kadlubar,F.F. (1994) Analysis of 4-aminobiphenyl-DNA
aducts in human urinary bladder and lung by alkaline hydrolysis and
negative ion gas chromatography-mass spectrometry. Environ. Health
Perspect., 102, 11-16.
22.Talaska,G., Schamer.M., Skipper.P. et al. (1991) Detection of carcinogen-
DNA aducts in exfoliated urothelial cells of cigarette smokers: association
with smoking, hemoglobin adducts, and urinary mutagenicity. Cancer
Epidemiol. Biomarkers Prev., 1, 61-66.
23. Auerbach.O. and Garfinkel.L. (1989) Histologic changes in the urinary
bladder in relation to cigarette smoking and use of artificial sweeteners.
Cancer, 64, 983-987.
24. Badawi,A., Hirvonen.A., Bell.D., Lang.M. and Kadlubar,F.F. (1995) Role
of aromatic amine acetyltransferases, NAT1 and NAT2, in carcinogen
DNA adduct formation in the human urinary bladder. Cancer Res., 55,
5230-5237.
25.Zhang,YJ., Chen,C, Lee.C, Haghighi,B., Yang.G., Wang.L., Feitelson.M.
and Santella,R.M. (1991) Aflatoxin Bl-DNA adducts and hepatitis B virus
antigens in hepatocellular carcinoma and non-tumorous liver tissue.
Carcinogenesis, 12, 2247-2252.
26.Chen,C, Zhang.Y.J., Lu,S. and Santella,R.M. (1992) Aflatoxin Bl-DNA
adducts in smeared tumor tissue from patients with hepatocellular
carcinoma. Hepatology, 16, 1150-1155.
27. Zhang, YJ., Hsu.T.M. and Santella,R.M. (1995) Immunoperoxidase
detection of polycyclic aromatic hydrocarbon-DNA adducts in oral mucosa
cells of smokers and nonsmokers. Cancer Epidemiol. Biomarkers Prev.,
4, 133-138.
28.Motykiewicz,G., Malusecka,E., Grzybowska,E., Chorazy.M., Zhang,YJ.,
Perera,F. and Santella,R.M. (1995) Immunohistochemical detection of
polycyclic aromatic hydrocarbon-DNA adducts in human lymphocytes.
Cancer Res., 55, 1417-1422
29. Shamsuddin.A.K.M. and Gan.R. (1988) Immunocytochemical localization
of benzo[a]pyrene-DNA adducts in human tissues. Hum. Pathology, 19,
309-315.
3O.Miller,M.R., Seiler.F., ThomaleJ., Buschfort.C, Rajewsky.M.F., and
Seeber.S. (1994) Capacity of individual chronic lymphatic leukemia
lymphocytes and leukemic blast cells for repair of O6-ethylguanine in
DNA: relation to chemosensitivity in vitro and treatment outcome. Cancer
Res., 54, 4524-4531.
Received on January 24, 1996; revised on March 6, 1996; accepted on March
11, 1996
916
 at European Institute of O
ncology on M
ay 12, 2016
http://carcin.oxfordjournals.org/
D
ow
nloaded from
 
